FDA mandates blindness warning on Ozempic, Wegovy and other GLP-1 weight‑loss drugs
FDA orders warning labels on Ozempic, Wegovy and other GLP‑1 weight‑loss drugs after rare eye disease linked to blindness emerges, prompting safety updates.
POLICY WIRE — Washington, D.C., United States — The U.S. Food and Drug Administration announced it will require manufacturers of GLP‑1 receptor agonist drugs to place a new safety warning on their product labels.
Products such as Ozempic, Wegovy and Mounjaro, used for diabetes management and weight loss, must now carry a notice about a rare ocular condition that can lead to permanent vision loss.
The agency cited emerging case reports linking the drugs to the condition, prompting a Drug Safety Communication and a mandate for label revisions to alert patients and clinicians.
The warning does not imply that all users will develop the issue, but underscores the importance of monitoring eye health while on GLP‑1 therapies.
Reporting by Policy-Wire (PW)